A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Latest Information Update: 29 Oct 2021
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Sep 2021 Number of treatment arms have been increased from 2 to 3 by the addition of one more arm to the phase 2 part consisting of Experimental: NAB-PACLITAXEL.
- 07 Sep 2021 Status changed from active, no longer recruiting to completed.
- 05 Mar 2020 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.